Patents by Inventor Jami MANDELIN

Jami MANDELIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stable anti-clever-1 antibody formulation
    Patent number: 12662533
    Abstract: The invention relates to stable formulations comprising an anti-CLEVER-1 antibody or antigen binding fragment(s) thereof, a buffer and a stabilizing agent. The present invention further relates to stable formulations of an anti-CLEVER-1 antibody or antigen binding fragments thereof for use in treatment of various diseases and disorders.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: June 23, 2026
    Assignee: Faron Pharmaceuticals OY
    Inventors: Jami Mandelin, Marita Vainio
  • Method for determining potency of therapeutic anti-clever-1 antibody
    Patent number: 12553906
    Abstract: A method for determining a potency of a therapeutic anti-Clever-1 antibody or fragment(s) thereof capable of binding to human Clever-1 by inhibition of a modified low-density lipoprotein uptake, wherein the inhibition of modified low-density lipoprotein uptake is an indication of biological activity of said anti-Clever-1 antibody or fragment(s) thereof.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: February 17, 2026
    Assignee: Faron Pharmaceuticals Oy
    Inventors: Juho Jalkanen, Jami Mandelin, Matti Karvonen
  • STABLE ANTI-CLEVER-1 ANTIBODY FORMULATION
    Publication number: 20230235046
    Abstract: The invention relates to stable formulations comprising an anti-CLEVER-1 antibody or antigen binding fragment(s) thereof, a buffer and a stabilizing agent. The present invention further relates to stable formulations of an anti-CLEVER-1 antibody or antigen binding fragments thereof for use in treatment of various diseases and disorders.
    Type: Application
    Filed: June 14, 2022
    Publication date: July 27, 2023
    Applicant: Faron Pharmaceuticals Oy
    Inventors: Jami MANDELIN, Marita VAINIO
  • TREATMENT OF DISEASES WITH CLEVER-1 INHIBITION IN COMBINATION WITH AN INTERLEUKIN INHIBITOR
    Publication number: 20230167173
    Abstract: Use of an agent capable of inhibiting CLEVER-1 expression or binding to CLEVER-1 in combination with an inhibitor of interleukin and/or the respective receptor, and optionally further with an agent capable of binding to interferon-alpha/beta receptor (IFNAR) in a treatment of diseases.
    Type: Application
    Filed: April 19, 2021
    Publication date: June 1, 2023
    Applicant: FARON PHARMACEUTICALS OY
    Inventors: Juho JALKANEN, Jami MANDELIN, Matti KARVONEN
  • ANTI-CLEVER-1 AGENTS FOR CONTROLLING THE EXPRESSION OF CELL SURFACE MARKERS ON LEUCOCYTES, AND USING THESE TO GUIDE ANTI-CLEVER-1 BASED CANCER TREATMENT
    Publication number: 20220404366
    Abstract: A method for monitoring a patient's response to anti-Clever-1 therapy and estimating the need for combination therapy based on the expression levels of one or more cell surface marker selected from PD-1, PD-L1, CTLA-4, ICOS, OX40, 41BB, LAG3, TIM3, CD28, CD25 and CXCR3 on leucocytes in relation to anti-Clever-1 treatment and choosing the best combination agent to initiate treatment together with anti-Clever-1 therapy after observed changes in one or more cell surface marker expression.
    Type: Application
    Filed: November 10, 2020
    Publication date: December 22, 2022
    Applicant: Faron Pharmaceuticals Oy
    Inventors: Maija-Leena HOLLMÉN, Reetta VIRTAKOIVU, Felix VAURA, Juho JALKANEN, Jami MANDELIN
  • METHOD FOR DETERMINING POTENCY OF THERAPEUTIC ANTI-CLEVER-1 ANTIBODY
    Publication number: 20220357348
    Abstract: A method for determining a potency of a therapeutic anti-Clever-1 antibody or fragment(s) thereof capable of binding to human Clever-1 by inhibition of a modified low-density lipoprotein uptake, wherein the inhibition of modified low-density lipoprotein uptake is an indication of biological activity of said anti-Clever-1 antibody or fragment(s) thereof.
    Type: Application
    Filed: September 23, 2020
    Publication date: November 10, 2022
    Applicant: Faron Pharmaceuticals Oy
    Inventors: Juho JALKANEN, Jami MANDELIN, Matti KARVONEN